Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07323524 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin in Active Lupus Nephritis
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT07323524 is a Phase 4 study that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 33 participants.
The verdict
NCT07323524, a Phase 4 study, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin (10Mg Tab) along with standard medical therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-05-19 |
| Est. Completion | 2030-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07323524
The ClinicalTrials.gov registry entry for NCT07323524 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07323524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07323524 about?
NCT07323524 is a clinical study titled "Dapagliflozin in Active Lupus Nephritis". Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidn...
What is the current status of trial NCT07323524?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2026-05-19. Estimated completion is 2030-01.
What interventions are being tested in trial NCT07323524?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (10Mg Tab) along with standard medical therapy (DRUG).
Who is sponsoring clinical trial NCT07323524?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.